Artemis Investment Management LLP Invests $1.71 Million in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Artemis Investment Management LLP bought 21,617 shares of ANI Pharmaceuticals in Q4, a new stake worth approximately $1.71 million, representing about 0.10% ownership.
• Other large institutions (including Arrowstreet, Balyasny and UBS) materially increased positions, leaving 76.05% of ANIP owned by institutional investors and hedge funds.
• Wall Street is generally positive on ANIP — average rating is “Moderate Buy” with an average price target of $107.33 (Guggenheim recently raised its target to $124) while the stock trades around $80 and the company has a market cap of about $1.8 billion.

Artemis Investment Management LLP acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 21,617 shares of the specialty pharmaceutical company's stock, valued at approximately $1,706,000. Artemis Investment Management LLP owned about 0.10% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership purchased a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Balyasny Asset Management L.P. raised its holdings in shares of ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Rubric Capital Management LP lifted its stake in shares of ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after buying an additional 200,998 shares during the period. Finally, UBS Group AG grew its holdings in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Up 1.2%

NASDAQ:ANIP opened at $80.39 on Friday. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.71 and a quick ratio of 2.19. The company's fifty day moving average price is $76.36 and its 200-day moving average price is $81.24. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The firm has a market capitalization of $1.80 billion, a P/E ratio of 23.93 and a beta of 0.46.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 2,084 shares of the company's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $77.53, for a total value of $161,572.52. Following the sale, the senior vice president owned 50,993 shares in the company, valued at $3,953,487.29. This represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the firm's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the sale, the senior vice president directly owned 38,730 shares in the company, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 27,860 shares of company stock worth $2,111,581. 8.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ANIP shares. Guggenheim upped their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Wall Street Zen cut ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, March 14th. Finally, Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $107.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.